Side-by-side · Research reference

5-Amino-1MQvsMatrixyl

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-MechanisticHUMAN-REVIEWED9/39 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

01Mechanism of Action

Parameter

5-Amino-1MQ

Matrixyl

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Dermal fibroblastsPaccola 2025

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Matrixyl

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

—

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

—

Duration

8–12 weeks per cycle

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Formulation concentration

—

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

Application frequency

—

Twice daily (AM/PM)

Standard cosmeceutical protocol.

In vitro evidence

—

Fibroblast viability + ECM gene upregulationPaccola 2025

Vehicle

—

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

04Side Effects & Safety

Parameter

5-Amino-1MQ

Matrixyl

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Irritation

—

Mild erythema, pruritus in sensitive skin (rare)

Allergic reaction

—

Contact dermatitis (uncommon)

Systemic absorption

—

Negligible — topical application only

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Matrixyl

·Active dermatitis or open wounds at application site

05Administration Protocol

Parameter

5-Amino-1MQ

Matrixyl

1. Form

Oral capsule. No injection.

Wash face with gentle cleanser. Pat dry.

2. Administration

Take with water, fasted preferred.

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

3. Timing

Morning fasted.

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

4. Storage

Room temp ≤25 °C, dry place.

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

5. Caveat

Monitor B-vitamin status with chronic use.

—

06Stack Synergy

5-Amino-1MQ

— no documented stacks

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity